SINOPSEE-THERAPEUTICS

Si NO PSEE Therapeutics is a bio-pharmaceutical company focused on the discovery, design, and development of small molecular weight compounds for the treatment of chronic diseases. It was founded in 2017 by a group of scientists from the Agency for Science, Technology & Research (A*STAR), in Singapore... Si NO PSEE Therapeutics is led by a team deeply rooted scientifically and passionate in novel drug discovery research. We have a long-standing prominent network globally with Key Opinion Leaders (KOL) and industrial experts. Our scientific advisors are highly regarded for successfully rolling novel molecules which have significantly contributed towards patient healthcare. As a dedicated team, we envision to impact patient-care through discovery, research, and development of novel therapeutics... VEGF is a validated therapeutic target for anti-angiogenic therapy. Current standard-of-care treatment includes FDA approved anti-VEGF inhibitors/antibodies Aflibercept (Eylea), Ranibizumab..